Projects
|
Development of topical Methima-zole UNIGE - Uni Genève Behrooz Kasree Development of topical Methima-zole Skin hyperpigmented lesions (mark of pregnancy, lenigos, post acne hyperpigmented scars etc.) are very frequent dermatologic problems. Such prob-lems have been treated since many years by creams containing hydroquinone as the active substance. Hydroquinone has been recently banned by FDA and European authorities since it has been identified as a toxic and carcinogenic compound. Methimazole is an FDA-approved oral medication used for the treatment of hyperthyroid-ism. We have shown, for the first time, that if methimazole is made into a cream (topical 5% methimazole) it removes the skin hyperpigmented lesions after 4-6 weeks of application in human. Our cell culture, animal and human studies have confirmed the safety and efficacy of topical methimazole as a skin depigmenting agent. We believe that this product has the potential to replace hydroquinone containing products and be widely commercialised in most countries. |
|
Weitere Informationen über diese Seite
IFJ Newsletter
Aktulle News aus dem Bereich Startup
direkt per E-Mail erhalten: